Immunovia AB 2025 AR2
The report highlights Immunovia's transition to a commercial-stage company in 2025 with the launch of its PancreaSure blood test for early pancreatic cancer detection in the United States. The company secured a Medicare reimbursement rate of $897 and expanded its clinical validation through peer-reviewed studies, including the CLARITI study. Immunovia also obtained College of American Pathologists accreditation for its North Carolina laboratory and signed a licensing agreement with Proteomedix to secure manufacturing independence. Financially, the company raised over SEK 140 million to fund its commercial launch and clinical programs.
Company: Immunovia AB
Sector: Professional & technical services
Country: Sweden
Year: 2025
Type: AR2
Pages: 71
Back to company
Immunovia AB
Annual Report
The report highlights Immunovia's transition to a commercial-stage company in 2025 with the launch of its PancreaSure blood test for early pancreatic cancer detection in the United States. The company secured a Medicare reimbursement rate of $897 and expanded its clinical validation through peer-reviewed studies, including the CLARITI study. Immunovia also obtained College of American Pathologists accreditation for its North Carolina laboratory and signed a licensing agreement with Proteomedix to secure manufacturing independence. Financially, the company raised over SEK 140 million to fund its commercial launch and clinical programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees